Medical Condition News

RSS

FDA approves Sinapis Pharma's IND for IV methamphetamine in treatment of acute stroke

Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.

12 Apr 2010

Over 12,000 participants already registered for 25th Anniversary EAU Congress

The upcoming 25th Anniversary EAU Congress in Barcelona from April 16 to 20 promises to be one of the EAU's biggest meetings in recent years with around 12,100 participants already registered to attend the annual urological event.

12 Apr 2010

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Inhibitex provides update on ongoing Phase II clinical trial of FV-100 for shingles

Inhibitex, Inc. today announced that the independent Data Safety Monitoring Board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with 30-day follow-up data on the first half of the patients that the Company plans to enroll in the trial.

12 Apr 2010

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies, Inc. announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device.

12 Apr 2010

Regenerating damaged organs by turning growth back on in normal cells

If you consider yourself to be too short or too tall, things are looking up, or down, depending on your vertical disposition. New research published online in The FASEB Journal explains how we grow, how our bodies maintain correct proportions, and offers insight into what goes wrong with growth disorders and unregulated cell growth in cancer.

12 Apr 2010

Results of research study on the expression of KIF6 in mouse model

Celera Corporation and its collaborators at The University of Washington, WA, and Indiana University, IN, today announced the presentation of data from a research study that investigated the expression of KIF6 in a mouse Celera Corporation model. A key finding was that KIF6 was specifically expressed in macrophages and chondrocytes in mouse atherosclerotic lesions, but not in normal arteries.

12 Apr 2010

Study explains why Hispanics are less likely to undergo colorectal cancer screening

A new study finds that Hispanics live in areas with more limited availability of colonoscopies and sigmoidoscopies for colorectal cancer screening. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that differences in areas' capacity for providing these procedures may explain why Hispanics are less likely to undergo colorectal cancer screening than non-Hispanic whites.

12 Apr 2010

Results of Phase I ThermoDox dose escalation trial to be discussed in a press conference

Celsion Corporation today announced that Dr. Ronnie T.P. Poon from the University of Hong Kong and lead principal investigator for the Asia Pacific region of the Phase I ThermoDox dose escalation trial will hold a press conference on Thursday, April 15, 2010 at 10:30 AM HKT (Wednesday, April 14, 2010 10:30 PM ET) to discuss the long-term follow-up of patients treated from April 2006 to December 2006.

12 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

New patient education video and guidebook for MS patients

Silver screen star Teri Garr is the host of the American Academy of Neurology Foundation's newest patient education video and guidebook, Living Well: A Guide to Managing Multiple Sclerosis for Patients and Families.

12 Apr 2010

MIF molecule plays crucial role in neurogenesis

There has been little progress in the way we treat depression and anxiety for over thirty years, but a recent study at EPFL Ecole Polytechnique Fédérale de Lausanne (EPFL) may open the door to new strategies. In an article published online February 23, 2010, in Molecular Psychiatry, researchers from two laboratories at the Brain Mind Institute at EPFL (Ecole Polytechnique Fédérale de Lausanne) explain how understanding the functioning of a molecule called MIF, or macrophage migration inhibitory factor, may change the way we treat depression.

12 Apr 2010

Aptium Oncology Myeloma Consortium launched

Aptium Oncology, Inc. today announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers.

12 Apr 2010

Meijer adds Metformin Immediate Release to free medication program

With diabetes affecting the lives of millions of people throughout the Midwest, Meijer announced plans today to begin offering Metformin Immediate Release, the most commonly prescribed treatment for type 2 diabetes, at no cost to those with a medical prescription. Meijer's program will include doses prescribed in 500mg, 850mg and 1000mg tablets.

12 Apr 2010

Eating fruit and vegetable slightly reduces risk of developing cancer: Study

Although eating more fruit and vegetables has been associated with cancer prevention for some time, it was not clear how strong the effect was.

12 Apr 2010

Tips to tide over the spring allergy season

Record snow, heavy early spring rains, followed by a rapid warm up have created the perfect storm for allergy season. But allergists from the American College of Allergy, Asthma and Immunology can offer ways to help people find relief.

12 Apr 2010

Brains on Bikes raises funds for brain cancer research and support

Anne Feeley, a 55-year-old mother and brain cancer survivor, began a 3,781-mile ride across the country today to raise money and awareness for brain cancer research and support.

12 Apr 2010

Gene playing crucial role in immune system balance identified

A team led by St. Jude researchers identified a gene pivotal for immune system balance. Ultimately, the discovery may aid efforts to tame allergies and asthma.

12 Apr 2010

High OOP costs discouraging many cancer patients from filling prescriptions

A new study presented today at the Academy of Managed Care Pharmacy's 22nd Annual Meeting finds that one in six cancer patients with high out-of-pocket (OOP) costs abandons their medication. The study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, found patients with an OOP cost greater than $200 were at least three times more likely to not fill their prescription than those with OOP costs of $100 or less.

12 Apr 2010

People without migraines can filter out more visual noise: Study

When people feel the onset of a migraine headache, they may head to a dark, quiet room to rest. This instinct may be sound: A new study suggests that even without the headache, migraine sufferers may process visual cues better in an environment with few visual distractions.

12 Apr 2010